[Form 4] Staar Surgical Co Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing overview – STAAR Surgical Co. (STAA)

On 18 June 2025, non-employee director Louis E. Silverman received an equity award under STAAR Surgical’s annual non-employee director compensation program. The transaction was reported on 20 June 2025.

• Security type: Restricted Stock Units (RSUs)
• Quantity granted: 10,683 RSUs, each representing the right to one share of common stock upon vesting
• Transaction code: “A” (grant, no open-market price; stated value $0)
• Vesting schedule: 100% on the earlier of 18 June 2026 or the company’s 2026 Annual Meeting of Shareholders
• Post-grant derivative holdings: 10,683 RSUs held directly

No open-market purchases or sales of common shares were reported, and the filing contains no indication of indirect ownership arrangements. The grant reflects routine board compensation and does not, by itself, alter STAAR Surgical’s capital structure or provide insight into operating performance, but it does align the director’s incentives with shareholder value over the coming year.

Insights

Corporate Governance Analyst

TL;DR: Routine annual RSU grant to director; neutral impact, signals standard shareholder-aligned compensation.

The filing records a single equity award of 10,683 RSUs to Director Louis E. Silverman, consistent with STAAR Surgical’s established non-employee director plan. There is no buying or selling of existing shares, no cash consideration, and the award vests in roughly one year. Such grants are common across U.S. public companies and are generally interpreted as neutral events: they neither dilute shareholders materially nor indicate an insider view on valuation. Investors may view the award as a modest alignment mechanism that ties board compensation to future share performance, but the scale (<1% of basic shares outstanding) is immaterial to valuation or float. Absent additional insider buying or selling activity, this disclosure should not influence investment decisions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SILVERMAN LOU

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	06/18/2025		A		10,683		(2)	(2)	Common Stock	10,683	$0	10,683	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting.

2. These equity awards vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.

Remarks:

This Form 4 reflects the equity awards granted to the Reporting Person on June 18, 2025, pursuant to the Corporation's annual non-employee director equity compensation program for the 2025-2026 term.

	/s/ Nathaniel Sisitsky as attorney-in-fact for Louis E. Silverman	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many STAAR Surgical (STAA) RSUs did Director Louis Silverman receive?

The Form 4 shows a grant of 10,683 restricted stock units on 18 June 2025.

When will the newly granted RSUs to Louis Silverman vest?

The RSUs vest in full on the earlier of 18 June 2026 or STAAR Surgical’s 2026 Annual Meeting.

Was there any open-market purchase or sale of STAA shares in this filing?

No. The report discloses only an equity grant; no purchases or sales of common stock were reported.

What transaction code appears in STAAR Surgical’s latest Form 4?

The filing uses transaction code “A”, indicating an equity award or grant.

Does the filing indicate indirect ownership by the director?

No. The ownership form is listed as Direct (D); no indirect holdings are disclosed.